News

Advarra will begin migrating legacy Schulman IRB study information into the Advarra electronic platform in May 2018. Clients will be contacted beginning in March to discuss the migration process and develop a transition plan.

Effective 2/5, Advarra IRB serves as the IRB providing oversight for the study(ies) listed on 1572s as under Schulman IRB oversight.

Advarra's President and COO Jeff Wendel was quoted in How EHRs Facilitate Clinical Research from Applied Clinical Trials.

Robann Cunningham has been named to the Healthcare Businesswomen’s Association (HBA) Cincinnati Chapter Board as the Director-at-Large for the Programming Committee.

TransPerfect Life Sciences announced today that it has been selected as the official language services provider for Advarra.

The Department of Health and Human Services (HHS) and 15 other agencies have issued an Interim Final Rule (IFR) that applies a 6 month delay to the effective date and general compliance date of the revisions to the “Federal Policy for the Protection of Human Subjects” (also known as the Common Rule) originally published in the Federal Register on January 19, 2017 (82 FR 7149).

Both Schulman IRB and Chesapeake IRB will retain d/b/a status for an interim period and continue to operate under the current structure.

As a part of ongoing integration efforts, Schulman IRB and Chesapeake IRB have developed a joint Fee Schedule for the combined Advarra organization.

Chesapeake IRB and Schulman IRB, the research industry’s two most respected institutional review boards (IRBs), have combined to create Advarra.